Clinical Trials
2 trialsNCT01246440 2016-08-11
Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Completed
NCT00189345 2006-11-08
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
AGO Study Group
Phase 2 Completed